Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Stack #119612
| Question | Answer |
|---|---|
| relationship b/w nature &intesity of biological effects produced in humans AND physicochemical properties of the drug formulation administered | BIOPHARMACEUTICS |
| biopharmaceutics factors my influence what of the drug | stability, release, dissolution and absorption |
| formulation properties of interest | type and process of dosage form, state, size, surface , and nature |
| pharmacokinetics literally mean in greak what | movement of drug |
| ADME stands for | absorption, distribution, metabolism, and excretion |
| when do you get a pharmacologic response | if the drug concentration at e hsite of actions exceeds the minimum effective concentration MEC |
| a measure of systemic availablity of a drug is called what and can determine whethere an administered drug is therapeutically effective, toxic, or has no apparent affect at all | bioavailability |
| what is a term that refers to the release of the drug at the absorption site | dissolution |
| in-vitro | lab |
| in-vivo | human |
| biopharmaceutics considers the | properties and dosage form in a phsiologic environment, therapeutic use, route of administration |
| a term for excretion and metabolim combined | elimination |
| distribution and elimination combined | drug disposition |
| two approaches to pharmacokinetics are | experimental and theoretical approach |
| which approach involves the development of biologic sampling techniques, analytical methodas for the measurement of drugs and metabolites, and prcedures that facilitate data collection and manipulation. | experimental aspect (three things) |
| which aspect of pharmacokinetics involves the development of pharmacokinetics models that predict drug disposition after drug adminsitration | theoretical aspect |
| what is the study of theoretical models focusing mostly on model development and parameterization | classical pharmacokinetics |
| drug concentration below MEC | subtherapeutic |
| drug concentration above the minimun toxic concentration | toxic response |
| what study of pharmacokinetics involve a multidisciplinary approach to individually optimized dosing strategies based on the patients disease state and patient-specific consideration | clinical ( requires input from medical an pharmaceutical research |
| the study of pharmacokinetic differences of drugs in various population groups is termed what | population pharmacokinetics |
| CPKS provides pharmacokinetic and drug ananlysis service for safe drug monitoring. it stands for | clinical pharmacokinetic service |
| pharmacokinetics is applied to TDM for very potent drugs to prevent any adverse toxicity. this stands for what | therapeutic drug moitoring (TDM) |
| what refers to the relationship between the drug concentration at the site of action( receptor) and pharmacologic response, including biochemical and physiological effects tha tinfluence the interaction of drug with teh receptor | pharmacodynamics |
| what will equal a response | drug plus and receptor |
| why do we have pharmacodynamic models | to relate plasma levels to concentraion over time |
| what application of pharmacokinetic priniciples is to design, conduct, and interprete drug safety evaluation studies and validate dose related exposure in animals | toxicokinets |
| what is the study of adverse effects of drugs and toxic substances (poisons) in the body | clinical toxicology |
| how can we measure drug concentration in the body through noninvasive methods | through samples of urine, sliva, feces, expired air, milk, and urine |
| measure of invasive ways to get drug concentration | sampling of blood, spinal fluid, synovial fluid, synovial fluid, tissure biopsy, or parental or surgical way |
| we use plas to obtaine drug concentration because we assume what | that plasma is in dynamic equilibrium with the tissues, reflecting changes in tissue drug concentration |
| elmination is done by what | exretion, biotransformation (fanacy word for metabolism) or can be by both |
| what reflects the minimum concentration of drug needed at the receptors to produce the desired pharmacoloic effect | MEC min effective concentration |
| what represents the drug concentration neeeded to just barely produce a toxi effect | MTC min tox effect |
| what on a graph corresponds to the time required for a drug to reach the MEC | onset time |
| what is proportional to the number of drug receptors occupied | intensity of the pharmacoligic effect |
| what is referred to as the difference between the onset time and the time for the drug to decline back to the MEC | duration of drug action |
| what is related to the amount of drug absorbed systemically | AUC |
| what three things can affect peak plasma level or maxiumum drug contration | the dose, rate constant for absorption, and elimination constant of the drug |
| what is an indirect way to ascertain the bioavailability of a drug. this reflets the rate and extent of systemic absorption | drug in the urine |
| a measure of saliva drug concentration is a measure of free drug or or total plasma drug concentration | free drug |
| what do pharmacokinetc models allow us to interpretate | the relationship between plasma drug levels and pharmacological response |
| when will plasma levels not be a good indicator of pharmacodynamic response | drugs that act irreversibly at the receptor site |
| drus in the body can do what three things | move freely, bind, or metabolize |
| Methods by which drug is kept in the body for extended action are ____, ____, and ______ the three major processes by which drug may be kept within the body | pH, protein binding and fat storage |
| We will assume that drug elimination follows _____ AND means that the rate of change of drug concentration by any process is DIRECTLY PROPORTINAL to the drug concentration remaining to undertake that process. | Remember first order kinetics is an assumption of a linear model not a one compartment model. if we double the dose, the concentration will double at each time point. |
| distinguish between the elimination rate and the elimination rate constant | The rate (tangent or slope, dCp/dt) changes as the concentration changes, however, for a linear model the rate constant (kel) is constant, it does not change. |
Created by:
lainylaina